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Background: Population-based surveys demonstrate cannabis users are more likely to
use both illicit and licit substances, compared with non-cannabis users. Few studies have
examined the substance use profiles of cannabis users referred for treatment. Co-existing
mental health symptoms and underlying cannabis-related beliefs associated with these
profiles remains unexplored.
Methods: Comprehensive drug use and dependence severity (Severity of Dependence
Scale-Cannabis) data were collected on a sample of 826 cannabis users referred for
treatment. Patients completed the General Health Questionnaire, Cannabis Expectancy
Questionnaire, Cannabis Refusal Self-Efficacy Questionnaire, and Positive Symptoms and
Manic-Excitement subscales of the Brief Psychiatric Rating Scale. Latent class analysis
was performed on last month use of drugs to identify patterns of multiple drug use. Mental
health comorbidity and cannabis beliefs were examined by identified drug use pattern.
Results: A three-class solution provided the best fit to the data: (1) cannabis and tobacco
users (n=176), (2) cannabis, tobacco, and alcohol users (n=498), and (3) wide-ranging sub-
stance users (n=132).Wide-ranging substance users (3) reported higher levels of cannabis
dependence severity, negative cannabis expectancies, lower opportunistic, and emotional
relief self-efficacy, higher levels of depression and anxiety and higher manic-excitement
and positive psychotic symptoms.
Conclusion: In a sample of cannabis users referred for treatment, wide-ranging substance
use was associated with elevated risk on measures of cannabis dependence, co-morbid
psychopathology, and dysfunctional cannabis cognitions. These findings have implications
for cognitive-behavioral assessment and treatment.
Keywords: cannabis, latent class, drugs, comorbidity, expectancy, self-efficacy, treatment seeking
INTRODUCTION
Between 2.8 and 4.5% of the world’s adult population have used
cannabis in the past year (1), making it globally the most widely
used illicit substance. General population estimates indicate that
up to 1.3% are cannabis dependent (2). Individuals who use
cannabis are also more likely to use other illicit substances (3).
The association between cannabis use and mental health prob-
lems is well documented (4, 5). Analyses of cannabis users in
population-based surveys have identified substance use ‘typolo-
gies’ though latent class modeling [e.g., (6)]. These typologies
can inform public health and targeted prevention approaches.
The ‘typology’ of cannabis users referred for treatment is likely to
differ from that in the general population. Polysubstance use, men-
tal health comorbidity and underlying acquired cannabis-related
beliefs associated with these substance use profiles require further
investigation.
Latent Class Analysis (LCA) has been widely applied in
population-based alcohol and drug research to estimate probabil-
ity of substance use sub-classes, or ‘typologies.’ Most generate class
solutions that include: (a) no or limited substance use, (b) moder-
ate substance use, and (c) wide-ranging substance use. In addition
to varying range of substances captured across studies, the final
number of class solutions and prevalence rates per solution varies
as a function of the population sampled and period of drug use
captured (typically lifetime or past 12 month use). For example, a
representative sample from the British National Household Survey
(n= 8538, mean age 42.55 years) generated a three-class solution
of 12 month illicit drug use: (1) no polydrug use (95.78%), (2)
moderate polydrug use (3.44%), and (3) wide-ranging polydrug
use (0.77%) (3). Based on lifetime illicit substance use data from an
Australian Twin Study (n= 6265, mean age 30 years), Lynskey et
al. (7) identified a 5-class model: (1) low use (68.5%), (2) moderate
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use of all substances (17.8%), (3) high use of stimulants and hal-
lucinogens and low use sedatives and opioids (6.6%), (4) high use
sedatives and opioids and low use of stimulants and hallucinogens
(3.0%), and (5) uniformly high use across all substances (4.2%).
Examining lifetime use of all substances (illicit and licit) of
younger age groups from the Australian National Drug Strategy
Household Survey (n= 1402, 12–17 years), White et al. (8) found
a three-class model that included: (1) alcohol only (79.6%), (2)
limited range multidrug users (18.3%), and extended range mul-
tidrug users (2%). In community-based samples of cannabis users
the percentage of wide-ranging substance use increases to 21%
(past 3 months) (9). The prevalence rates of de Dios et al.’s (9)
other two LCA cannabis classes were Unaffected/Mild Users (37%)
and Moderate Problem Users (42%).
Comparisons between studies are difficult because narrower
substance use time frames reduce prevalence rates. Targeting
specific substance using populations increases the prevalence of
polysubstance use. Broader timeframes (e.g., lifetime use) are less
reliable in reporting recent polysubstance use patterns. Narrower
assessment timeframes represent more clinically relevant data, but
can lack power because of the low prevalence of use of some
substances.
Mental health problems often co-occur with substance use dis-
orders, including psychotic-like symptoms (10–12). Substance use
LCA studies permit a more precise investigation of patterns of psy-
chiatric comorbidity. Wider-ranging LCA substance use classes
have previously been associated with elevated psychological dis-
tress (8), increased mood and anxiety problems, suicide attempts
(3, 7) and treatment seeking (3). When alcohol dependent subjects
are examined within population-based surveys, those classified by
LCA as having a high probability of heavy alcohol consumption as
well as heavy illicit drug use,are more likely to have co-existing gen-
eralized anxiety and major depressive disorders (13). Studies that
have extracted cannabis users from nationally representative data
sets, observe similar deficits in functioning within those classes
reporting higher risk for multiple substance use (6). These find-
ings suggest psychiatric severity increases linearly with increased
polysubstance use.
No LCA studies have examined the substance use profiles and
accompanying mental health comorbidity of individuals referred
for cannabis use treatment. These profiles are likely to be differ-
ent from population-based studies. To improve assessment and
treatment of this group, it is also of benefit to extend beyond
broader mental health functioning measures and examine addi-
tional etiological factors, especially cannabis-related beliefs which
can serve as targets for evidence-based psychological interven-
tions. Two such targets for cognitive-behavioral treatment are
outcome expectancies and substance-refusal self-efficacy. Both
carry strong Social Cognitive Theory (SCT) pedigrees (14–16).
Outcome expectancies are sometimes referred to as ‘if . . .
then’ statements that reflect the perceived behavioral and affective
consequences of engaging in specific behaviors (17). Cannabis
expectancy scales are typically represented by two higher-order
expectancy factors, representing positive (e.g., “I have more
self-confidence when smoking cannabis”) and negative (e.g.,
“Smoking cannabis makes me confused”) expectancies [see (18)].
Self-efficacy refers to a person’s belief they can successfully or
unsuccessfully regulate their behavior (e.g.,“I am very sure I could
not resist smoking cannabis when I feel upset”). Cannabis refusal
self-efficacy is considered a central psychological mechanism that
predicts post-treatment consumption (19) and abstinence (20,
21). Expectancy ‘challenges’ have been applied in alcohol use
prevention and treatment (22), but progress in cannabis has
been hampered by a lack of cannabis-specific assessment tools.
Cannabis expectancy and refusal self-efficacy scales have recently
been validated for use in clinical populations (18, 23).
Polysubstance use varies widely in definition. Here we define it
as two or more substances used in the past month. In this study of
cannabis users referred for treatment, we predicted a continuum
of past month polysubstance use that would range from cannabis
only (and no/low licit drug use) to wide-ranging polysubstance
use. We make no a priori assumptions about the number of LCA
solutions, but predicted a higher prevalence of polysubstance use
within wider-ranging profiles compared to community [e.g., (9)]
and general population [e.g., (3)] samples. Mental health function-
ing should be poorer across all class solutions, when compared
to community population norms. Consistent with the findings
of Lynskey et al. (7) and Smith et al. (3), symptoms of mood
and anxiety disorders are likely to be more impaired in users
with wider-ranging drug profiles. Psychotic-like symptoms, on
the other hand, are likely to show a dose-response relationship,
such that the classes with more severe cannabis dependence will
display a higher symptom severity (11). Patients who use cannabis
with no or limited other substance use are expected to have greater
opportunities to form more salient cannabis-related beliefs (18),
and should have higher cannabis expectancy and lower cannabis
refusal self-efficacy.
The main aim of this study is to identify polysubstance typolo-
gies for cannabis users in treatment. Based on these typologies,
it is expected that additional information on associated men-
tal health functioning and cognitive treatment targets will assist
researchers and health practitioners provide more effective assess-
ment approaches. These assessments are likely to result in more
tailored interventions for this group.
MATERIALS AND METHODS
PARTICIPANTS
The sample comprised 827 individuals who were referred for
assessment as part of the Queensland Illicit Drug Diversion Ini-
tiative (QIDDI). The program involves a 2-h comprehensive
assessment of substance use and psychosocial functioning that
incorporates motivational interviewing (MI). Where indicated,
referral for further treatment is provided. Of the 827 partici-
pants, 623 (77.2%) were men, and the mean age was 25.46 years
(SD= 8.35). The majority were born in Australia (692; 83.7%)
or New Zealand (53; 6.4%), and 49 (5.9%) identified themselves
as Indigenous Australians. Almost half (46.4%) scored above the
Severity of Dependence Scale-Cannabis (SDS-C) screening cut-
off for cannabis dependence [≥3, (24)]. Average weekly cannabis
consumption was 3.54 (SD= 4.90) g and the average SDS-C score
was 3.13 (SD= 3.20). Past month alcohol and other drug use is
presented in Table 1. The 4-week window was chosen to bet-
ter reflect current polysubstance use. Previous studies reporting
12 month or lifetime use have less clinical utility (e.g., a patient
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Table 1 | Past month alcohol and other drug use (N =827).
% used
in past
month
No. days used
in past month
Average
amount used
per occasion
Alcohol 84.8 6.87 (SD=8.46) 76.46 g (SD=82.99)
Tobacco 64.8 27.31 (SD=7.56) 14.13 (SD=9.13)
Amphetamine 17.4 2.88 (SD=4.32) 2.08 ‘points’ (SD=2.41)
Ecstasy/MDMA 13.2 2.15 (SD=2.36) 1.40 ‘tabs’ (SD=1.15)
Heroin 4.5 8.32 (SD=10.57) 3.87 g (SD=11.02)
Benzodiazepines 4.2 15.09 (SD=12.52) 16.88 mg (SD=23.23)
A ‘point’ is approximately 0.1 g.
who used cannabis once and alcohol once would fit criteria of a
polysubstance user in lifetime studies). Of the original sample, 20
participants (2.4%) were excluded from the main analysis due to
missing values on one or more drug-related variables, leaving a
final sample of 807 cases. This sample was drawn from an ongoing
clinical study conducted in an alcohol and drug outpatient set-
ting. Connor et al. (18, forthcoming) and Young et al. (23) have
used these data to validate cannabis expectancy and self-efficacy
measures. Feeney et al. (25) examined the differences in mental
health functioning between those who were and were not depen-
dent on cannabis, as well as providing descriptive drug use data on
12 month and lifetime use. Human ethics approval was obtained
from the Metro South Hospital and Health Service.
MEASURES
Cannabis expectancy questionnaire
The Cannabis Expectancy Questionnaire (CEQ) is a 45-item ques-
tionnaire assessing positive (18 items, e.g., “I get better ideas when
smoking cannabis”) and negative (27 items, e.g., “I am more wor-
ried about what others are saying about me when I am smoking
cannabis”) cannabis use outcome expectancies (18, 26). There is
a 5-point, Likert-style response format (1= Strongly Disagree to
5= Strongly Agree). The questionnaire was initially developed with
a community sample and validated on a large sample of cannabis
users recruited from a hospital outpatient clinic. The two sub-
scales have high internal reliability (α≥ 0.90), and the CEQ’s factor
structure and criterion validity have been established across two
samples (18).
Cannabis refusal self-efficacy questionnaire
The Cannabis Refusal Self-Efficacy Questionnaire (CRSEQ) is
a 14-item questionnaire assessing an individual’s belief in their
ability to resist smoking cannabis across various situations (23,
27). Items ask respondents to rate their ability to resist smoking
cannabis on a 6-point Likert-type scale ranging from 1 (I am very
sure I could NOT resist smoking cannabis) to 6 (I am very sure
I could resist smoking cannabis). Similar to the Drinking Refusal
Self-Efficacy Questionnaire [DRSEQ; (28)], it comprises three
subscales: Emotional Relief Self-Efficacy (six items, e.g., “When I
feel upset”), Opportunistic Self-Efficacy (five items, e.g., “When
someone offers me a smoke”), and Social Facilitation Self-Efficacy
(three items, e.g., “When I want to feel more confident”). The
questionnaire was developed with a community sample and
validated on a large sample of cannabis users recruited from
an outpatient treatment service. The internal reliability is
good/excellent (α= 0.84–0.97), and its factor structure and cri-
terion validity has been previously established (23).
Severity of dependence scale-cannabis
The SDS-C is a 5-item screening questionnaire measuring the
severity of cannabis dependence (29). The SDS-C is sensitive to
severity of cannabis dependence (30). Using Australian normative
data, the SDS-C cut-off for likely cannabis dependence is≥3 (24).
General health questionnaire-28
The General Health Questionnaire-28 (GHQ-28) is a 28-item
self-report measure which identifies short-term changes in health
perception (31). It has four sub-scales (i) Somatic Symptoms,
(ii) Anxiety, (iii) Social Dysfunction, and (iv) Depression (31).
Higher sub-scale scores reflect poorer functioning. The GHQ-
28 is a widely used measure of psychological health with strong
psychometric properties (31–33).
Psychotic-like symptoms
Psychotic-like symptoms were assessed using the Positive Symp-
toms (five items) and Manic-Excitement (six items) sub-scales of
the 24-item Brief Psychiatric Rating Scale [BPRS; (34)]. The BRPS
is a clinician-rated scale measuring 24 different psychiatric symp-
toms, each rated on a 7-point scale, ranging from 1 (not present )
to 7 (extremely severe). It is a reliable and valid measure of psy-
chiatric symptoms (35), and has previously been administered
to assess psychotic-like symptoms in injecting drug users (36).
Masters- and PhD-qualified clinical psychologists administered
the BPRS. Psychologists had between 2 and 25 years experience
(M = 10.5 years).
Quantity and frequency
Quantity and frequency of alcohol and other drug use in the
past month was assessed by Masters- and PhD-qualified clini-
cal psychologists using a retrospective diary approach over the
past month, past 12 months, and lifetime. As recommended by
the State Health Service, to ensure consistent measurement of
cannabis quantity across state-wide clinics ‘joints’ (cannabis cig-
arette) were quantified as 0.25 g of cannabis, and ‘cones’ (use of
‘bong’ or ‘pipe’), 0.10 g of cannabis.
ANALYSIS
Latent class analysis was performed to identify patterns of mul-
tiple drug use using last month use of seven drugs: cannabis,
alcohol, amphetamine, heroin, benzodiazepine, ecstasy (MDMA),
and tobacco. LCA is a technique that identifies sub-classes within
a population based on similarity of response to measured vari-
ables (37). This technique is characterized by two sets of para-
meters: (1) The estimated proportion of each class in the pop-
ulation and (2) the probability of an individual in a particular
class using a certain drug. Determination of the correct num-
ber of classes was based on the Bootstrap Likelihood Ratio Test
(38) and Sample Size Adjusted Bayesian Information Criterion
[SSABIC; (39)]. These two criteria have shown excellent per-
formance in identifying the correct number of classes (40). In
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BLRT, a significant p-value indicates that a given model fits the
data better than a model with one less class. For SSABIC, a
lower value indicates better balance between model parsimony
and model fit. In addition to these two criteria, the average
posterior probabilities of class membership were used to eval-
uate classification quality. Average posterior probabilities close
to one suggest clear classification. Model fitting began with a
1-class solution, and the number of classes was successively
increased up to a 4-class solution. Once the optimal number
of classes was determined, the profiles of participants in differ-
ent classes were compared using ANOVA, Kruskal–Wallis, and
χ2 test.
RESULTS
Model fit statistics for 1–4 class solutions are presented in Table 2.
The 3-class solution had the lowest SSABIC and results from the
BLRT indicate that it fitted the data significantly better than a 2-
class solution, but not worse than the 4-class solution. In addition,
the average posterior probabilities of class membership of a 3-
class solution were over 0.90, which indicated clear classification.
Therefore, it was selected as the optimal model.
Figure 1 shows the probability of last month use for each
substance by class. Class 1 was characterized by wide-ranging
substance use. Participants in this class had a high probability
of cannabis, tobacco, alcohol, and amphetamine use, a moderate
probability of ecstasy use, and a low probability of heroin and ben-
zodiazepine use. This class was labeled as wide-ranging substance
use, and the prevalence estimate of this class was 189 (23.5%).
Table 2 | Fit statistics of the unconditional latent class analysis.
Loglikelihood BIC SSABIC BLRT p-value
1 Class −2216.117 4479.087 4456.858
2 Classes −2168.662 4437.723 4390.090 <0.001
3 Classes −2153.480 4460.907 4387.869 <0.001
4 Classes −2145.417 4498.326 4399.883 0.21
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Class 1
Class 2
Class 3
FIGURE 1 | Probability of last month substance use from the 3-class
solution.
Class 2 was characterized by universal alcohol use, high probabil-
ity of cannabis and tobacco use, and negligible probability of other
drug use. This class was labeled as cannabis, alcohol, and tobacco,
and the prevalence estimate of this class was 458 (56.8%). Class 3
was characterized by a high probability of cannabis and tobacco
use, but negligible probability of other drug use. This class was
labeled as cannabis and tobacco, and the prevalence estimate was
156 (19.8%).
Table 3 shows the profiles of the three classes. Partici-
pants in the wide-ranging substance use class had significantly
higher negative cannabis expectancy, anxiety, and depression
scores, lower emotional relief self-efficacy and lower social facil-
itation self-efficacy, and higher manic-excitement and positive
psychotic symptoms (p < 0.05). They were also more likely
to be cannabis dependent (p < 0.05). However, as shown in
Table 3, the effect sizes were generally small, and in the case of
psychotic-like symptoms, were very low in all groups. Cannabis
users scored significantly higher than the Australian norma-
tive sample [Somatic Symptoms. 84, Anxiety. 77, Social Dys-
function. 64, Depression. 21; (41)] on all GHQ-28 subscales
(ps< 0.05).
DISCUSSION
This is the first study to examine the substance use profiles
and co-existing mental health symptoms of individuals referred
for cannabis use treatment, applying LCA. Previous LCA stud-
ies in cannabis users drawn from population and community
samples typically assess lifetime or past 12 month use. To more
precisely examine current polysubstance use, we restricted the
timeframe to the past 4 weeks. LCA generated a three-class solu-
tion that included Class (1) Wide-Ranging Substance Use, Class
(2) Cannabis, Alcohol, and Tobacco Use, and Class (3) Cannabis
and Tobacco Use. As anticipated, prevalence rates of substance
use were markedly higher than population-based studies. Class
1 patients represented approximately one quarter of the sample.
They reported a high probability of cannabis, tobacco, alcohol,
and amphetamine use, as well as moderate ecstasy use and low
heroin and benzodiazepine use in the previous month. Class 1 also
had significantly higher levels of cannabis dependence. Represent-
ing just over half of the sample, Class 2 had high probabilities of
alcohol, cannabis, and tobacco use, with limited other drug use.
The final LCA solution (Class 3) consisting of approximately one
fifth of the sample were characterized by low probability of alco-
hol and other drug use, but frequent cannabis and tobacco use.
Given the shorter time period under investigation compared to
population-based studies, this finding is particularly significant.
Across all three classes, mental health functioning of patients
was significantly more impaired than community norms (41).
Also consistent with our hypotheses, patients classified as
Wide-Ranging Substance Users (Class 1) had significantly higher
Depression and Anxiety scores than Classes 2 and 3. Wide-
Ranging Substance Users also displayed significantly higher pos-
itive psychotic-like and manic symptoms compared to Class 2
(Cannabis, Alcohol, and Tobacco Use). However, given the low
prevalence of such symptoms across all groups, this finding should
be interpreted with some caution. These findings are similar to
population-based LCAs that have measured mood and anxiety
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Table 3 | Profile of the three substance use classes.
Wide-ranging substance use Cannabis, alcohol, and tobacco Cannabis and tobacco F η2
N M SD N M SD N M SD
Age 132 24.92 6.45 498 25.16 8.61 176 26.79 8.77 2.85 0.007
CANNABIS EXPECTANCY
Positive expectancy 120 49.85 11.44 450 49.78 10.71 153 50.07 11.78 0.04 0.001
Negative expectancy 117 69.63a 17.31 449 63.10b 16.38 147 61.83b 16.34 8.72*** 0.024
GHQ SUBSCALES
Somatic symptoms 131 1.23 1.68 499 0.91 1.44 175 0.84 1.41 3 0.008
Anxiety 131 1.60a 1.98 498 1.05b 1.69 175 1.10b 1.7 5.15** 0.013
Social dysfunction 131 0.87 1.41 496 0.7 1.41 172 0.84 1.52 1.11 0.003
Depression 131 0.85a 1.65 496 0.46b 1.28 172 0.60ab 1.55 3.94* 0.01
CANNABIS REFUSAL SELF-EFFICACY
Emotional relief self-efficacy 120 21.93a 9.75 457 24.70b 9.01 149 23.39ab 9.13 4.73** 0.013
Opportunistic self-efficacy 121 15.63a 7.68 448 17.40ab 7.49 150 18.09b 7.5 3.83* 0.011
Social Facilitation self-efficacy 122 14.38 3.92 456 15.01 3.45 151 14.68 3.38 1.76 0.001
BRIEF PSYCHIATRIC RATING SCALE
BPRS positive symptoms
†
131 5.66a 1.35 499 5.48b 1.44 172 5.46ab 1.32 p=0.022
BPRS manic-excitement
†
131 7.17a 1.91 498 6.69b 1.58 172 7.05ab 2.20 p=0.007
N % N % N % χ2 Cramer’sV
GENDER
Male 103 78.03 394 79.12 125 71.02 4.9 0.078
Female 29 21.97 104 20.88 51 28.98
CANNABIS DEPENDENT
Dependent 76 57.58 213 42.77 85 48.3 9.52** 0.109
Not dependent 56 42.42 285 57.23 91 51.7
abMeans with the same superscript were not significantly different.
† Overall group difference tested using Kruskal–Wallis test. Follow-up pairwise comparisons tested using Mann–Whitney U tests with a Bonferroni-like adjustment to
α (0.05/3=0.016).
*p< 0.05; **p<0.01; ***p<0.001.
(3, 7), as well as more broadly defined psychological distress (8).
This study provides additional evidence that cannabis users in
treatment have a higher prevalence of poor co-morbid mental
health functioning. Severity of mental health dysfunction increases
when substances other than alcohol and tobacco are introduced.
In this young population of cannabis users, a clinically impor-
tant finding was low probability of alcohol use in Class 3 (frequent
cannabis and tobacco use only). Our original research hypothe-
ses anticipated that patients who limited use of substances to
cannabis only were expected to have more salient cannabis-related
beliefs, and should have higher cannabis expectancy and lower
cannabis refusal self-efficacy scores. In contrast, the Wide-Ranging
Substance group (Class 1) reported significantly higher negative
cannabis expectancies and lower emotional relief and opportunis-
tic cannabis refusal self-efficacy beliefs, when compared to Class 2
and 3. In alcohol studies, consistent with SCT (14, 15), this combi-
nation of high expectancies and low self-efficacy has been associ-
ated with highest levels of consumption [e.g., (42–44)] and poorest
treatment outcomes [e.g., (45)]. More recently, the combination
of high expectancy/low self-efficacy has been demonstrated to be
predictive of higher levels of cannabis dependence and cannabis
consumption (Connor et al., forthcoming), placing wide-ranging
substance users at elevated risk.
Given the psychometric similarity between expectancy and self-
efficacy factors across drug classes (Connor et al., forthcoming),
drug specific scales may be capturing additional risk of using
multiple drugs. Support for this can be observed with generic, non-
drug (general) self-efficacy being highly associated with substance
use (46). Front line treatments for cannabis use disorders that
hold strongest evidence for efficacy include Cognitive-Behavioral
Therapy (CBT), MI, and Contingency Management (CM) (47).
In the country this study was undertaken (Australia), CBT and
MI are most widely used. Both expectancy and self-efficacy are
key targets for CBT-based addiction treatments [e.g., (19, 22, 45)].
Cannabis users engaging in wide-ranging substance use may bene-
fit from greater focus on enhancing strategies to cope with distress
(for emotional relief self-efficacy, anxiety, depression) and general
refusal skills (for opportunistic self-efficacy), and less on building
motivation for change (negative expectancies).
The research has some limitations. The cross-sectional design
does not allow interpretation of causality. Substance use was
assessed though self-report. Biological verification would provide
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a more robust assessment of substance use. The design does not
allow assessment of the specific role of cannabis versus other
drugs in the severity of co-existing mental health problems, or
cannabis-related cognitions. While the sample size for a clin-
ical population is robust, the findings may not be generaliz-
able to all treatment seeking populations. All patients attended
under court direction as an alternative to a criminal prosecu-
tion. This may have had a proximal effect on self-reported health
and functioning. Future work could assess patients over multi-
ple time points to detect changes in substance use, mental health
functioning, and cannabis-related beliefs. Prospective compar-
isons between patients formally engaged in cannabis treatment
could assess the prognostic capacity of the three cannabis groups
identified.
This LCA study in a group of cannabis users diverted to treat-
ment identified that high levels of cannabis dependence and
illicit polysubstance use were strongly associated with impaired
mood and anxiety, as well as higher positive psychotic-like and
manic symptoms. Treatment approaches for this more complex
group may include combined CBT and pharmacotherapy to more
effectively target these symptoms directly. Patients with wide-
ranging substance use profiles may additionally benefit from
psychologically based strategies that focus on more effectively cop-
ing with symptom distress. Based on findings that this higher risk
profile has lower cannabis refusal self-efficacy beliefs, enhancing
skills, and confidence to resist situational cues through behavioral
training may provide additional clinical benefit in this higher risk
group.
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